FDA approvals, clinical trial results, insurance coverage changes, and breakthrough research in transcranial magnetic stimulation.
Our pick of the latest must-read TMS news.
A six-site replication of the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol reported 79% remission at four weeks in patients who had failed at least three prior antidepressants.
Read full coverage →46 stories on FDA approvals, clinical trials, and emerging research.
A six-site replication of the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol reported 79% remission at four weeks in patients who had failed at least three prior antidepressants.
Read more →Aetna updated its clinical policy bulletin to cover accelerated and SAINT-style TMS protocols without requiring patients to first complete a standard six-week course.
Read more →An FDA advisory committee voted 9-2 in favor of expanding TMS labeling to include adolescents aged 15-21 with treatment-resistant depression.
Read more →A 184-patient sham-controlled trial reported clinically meaningful pain reductions in patients with chronic neuropathic pain following five weeks of motor cortex TMS.
Read more →A randomized trial conducted in three urban emergency departments found a single accelerated TMS session reduced acute suicidal ideation scores within 24 hours.
Read more →Hologic acquired Danish TMS device maker MagVenture for $1.2 billion, the largest M&A transaction in the TMS sector to date.
Read more →A Stanford-led study found 20 sessions of theta burst TMS improved working memory in healthy older adults, with effects persisting at one month.
Read more →A 220-patient randomized trial found six weeks of TMS reduced postpartum depression symptoms with response rates comparable to antidepressants, without exposing breastfeeding infants to medication.
Read more →The FDA cleared single-pulse TMS devices for acute treatment of migraine without aura, expanding from the previous label limited to migraine with aura.
Read more →The FDA issued warning letters to several websites marketing TMS-like devices direct to consumers without prescription, citing risks from unsupervised use.
Read more →A 412-patient European trial reported that contralesional inhibitory TMS combined with standard rehabilitation produced significantly better motor recovery at 90 days post-stroke than rehabilitation alone.
Read more →The Department of Veterans Affairs updated its national clinical guidance to cover TMS for PTSD as a primary indication, regardless of whether comorbid depression is present.
Read more →A 60-patient pilot trial reported clinically meaningful weight stabilization and reduced rumination in patients with severe enduring anorexia nervosa following 30 sessions of dorsomedial prefrontal cortex TMS.
Read more →An AHRQ-commissioned cost-effectiveness analysis found TMS is cost-effective compared with continued sequential antidepressant trials for treatment-resistant depression.
Read more →A meta-analysis of 42 randomized controlled trials with 4,200 patients found intermittent theta burst stimulation produces equivalent depression outcomes to standard 10Hz TMS in roughly a third of the session time.
Read more →A 308-patient pivotal trial reported clinically meaningful tinnitus reduction at 12 weeks with a personalized TMS protocol, supporting an FDA submission expected in 2026.
Read more →Neuronetics reported positive topline results from its pivotal trial of NeuroStar TMS in adolescents with treatment-resistant depression.
Read more →Leading TMS device manufacturers Neuronetics and BrainsWay reached a cross-licensing agreement ending a multi-year patent dispute over coil designs.
Read more →A national survey of TMS clinics found 60% report difficulty hiring qualified operators, prompting calls for standardized certification pathways.
Read more →A 380-patient NIH-funded study found TMS can be safely used in bipolar depression when patients are stable on mood stabilizers, with mania-switch rates comparable to background population risk.
Read more →Magnus Medical raised $90 million in Series C funding to scale commercial deployment of its SAINT-style accelerated TMS protocol.
Read more →A 180-patient Phase II trial reported reduced self-reported cocaine use and craving following a four-week course of left dorsolateral prefrontal cortex TMS in patients pursuing abstinence.
Read more →The FDA cleared an updated, shorter deep TMS protocol for adult smoking cessation, reducing the standard course from six weeks to three.
Read more →Cigna updated its behavioral health policy to cover deep TMS for OCD as a primary treatment option, removing the prior requirement for failed antidepressant trials.
Read more →A 215-patient multi-site trial reported significant anxiety reductions in patients with generalized anxiety disorder following six weeks of right dorsolateral prefrontal cortex TMS.
Read more →A Phase II trial reported 78% remission at four weeks for combined TMS and intravenous ketamine compared with 45% for TMS alone and 39% for ketamine alone.
Read more →A 76-patient pilot study found four weeks of TMS produced clinically meaningful improvements in attention and processing speed in patients with persistent post-COVID cognitive symptoms.
Read more →Six state Medicaid programs added or expanded coverage for TMS in the first half of 2025, bringing total state coverage to 38 states.
Read more →A UMass-led analysis of 12,000 patients treated in community clinics found response and remission rates exceeded those reported in industry-sponsored randomized trials.
Read more →The AMA added two new CPT codes that distinguish theta burst stimulation from standard 10Hz TMS, supporting differential payer reimbursement and tracking.
Read more →The FDA granted breakthrough device designation for a TMS protocol targeting cognitive symptoms in mild Alzheimer's disease, expediting review of pivotal trial data.
Read more →A 54-patient pilot study reported reductions in affective instability and impulsivity in patients with borderline personality disorder following four weeks of dorsolateral prefrontal cortex TMS.
Read more →CMS proposed updated reimbursement rates for TMS CPT codes that would link a portion of payment to patient-reported outcome data submitted by treating clinics.
Read more →The FDA cleared an expanded indication for Neuronetics' NeuroStar to include anxious depression, the first device-specific clearance for this subtype.
Read more →A pediatric TMS safety registry reported no seizures or serious adverse events across 1,200 adolescents treated for depression at academic medical centers.
Read more →A 12-site sham-controlled trial of 360 adults with ADHD found six weeks of prefrontal TMS improved attention and working memory in patients who were not currently taking stimulant medications.
Read more →A 48-patient pilot trial reported reduced tremor amplitude in patients with essential tremor following 10 sessions of cerebellar TMS.
Read more →A national survey found 73% of psychiatrists now refer patients for transcranial magnetic stimulation, a substantial increase from 41% in a comparable 2020 survey.
Read more →The UK National Institute for Health and Care Excellence issued positive guidance recommending NHS coverage of TMS for fibromyalgia pain, pending cost-effectiveness review.
Read more →CMS issued guidance encouraging Medicare Advantage plans to adopt standardized TMS prior authorization criteria, addressing wide variability that had created access barriers.
Read more →NeuroSphere received FDA clearance for the first home-use TMS device for depression maintenance in previously-treated patients, requiring clinic enrollment and remote monitoring.
Read more →A 96-patient sham-controlled trial reported reduced binge-purge frequency in bulimia nervosa following four weeks of dorsolateral prefrontal cortex TMS.
Read more →A systematic review of TMS during pregnancy across 22 studies and roughly 380 pregnancies found no signal of increased risk to mother or fetus.
Read more →The Clinical TMS Society released results from the first comprehensive registry of real-world TMS outcomes, finding 55% response and 31% remission rates across 50,000 patients.
Read more →A 12-month follow-up study of patients treated with deep TMS for obsessive-compulsive disorder found 62% of initial responders maintained meaningful improvement at one year.
Read more →CMS authorized Medicare reimbursement for transcranial magnetic stimulation delivered under telehealth physician supervision in rural and underserved areas.
Read more →Disclaimer: News items are for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare provider regarding treatment decisions.
With all this promising research, see if TMS therapy is right for you.
Get instant access to our comprehensive guide